均龙胆酸
黄斑病
碱尿
黑色素
抗坏血酸
氧化应激
酪氨酸酶
生物化学
体外
牛磺酸
医学
药理学
化学
氨基酸
酶
病理
食品科学
作者
Daniela Braconi,Marcella Laschi,Loredana Amato,Giulia Bernardini,Lia Millucci,R. Marcolongo,Giovanni Cavallo,Adriano Spreafico,Annalisa Santucci
出处
期刊:Rheumatology
[Oxford University Press]
日期:2010-07-02
卷期号:49 (10): 1975-1983
被引量:47
标识
DOI:10.1093/rheumatology/keq175
摘要
Alkaptonuria (AKU) is a rare genetic disease associated with deficient homogentisate 1,2-dioxygenase activity in the liver. This leads to the accumulation of homogentisic acid (HGA) and its oxidized/polymerized products in connective tissues, which in turn become characterized by the presence of melanin-like pigments (ochronosis). Since at present, further studies are necessary to support the use of drugs for the treatment of AKU, we investigated the effects of various anti-oxidants in counteracting melanin-like pigmentation and oxidative stress related to HGA and its metabolites.We set up an in vitro model using human serum treated with 0.33 mM HGA and tested the anti-oxidants ascorbic acid, N-acetylcysteine, phytic acid (PHY), taurine (TAU), ferulic acid (FER) and lipoic acid (LIP) for their ability to prevent or delay the production of melanin-like pigments, as well as to reduce oxidative post-translational modifications of proteins. Monitoring of intrinsic fluorescence of HGA-induced melanin-like pigments was used to evaluate the efficacy of compounds.Our model allowed us to prove efficacy especially for PHY, TAU, LIP and FER in counteracting the production of HGA-induced melanin-like pigments and protein oxidation induced by HGA and its metabolites.Our model allows the opening of new anti-oxidant therapeutic strategies to treat alkaptonuric ochronosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI